Yabing Guo

机构：Nanfang Hospital, Southern Medical University

发表论文 81 篇 · 总被引 3197 次 · h-index 23

代表论文

• Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) (2023 · Liver Cancer · 被引 465)
• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 45)
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 41)
• Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial (2024 · BMC Medicine · 被引 33)
• Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study (2022 · Frontiers in Oncology · 被引 33)
• TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma. (2022 · Journal of Clinical Oncology · 被引 27)